Results 91 to 100 of about 22,562,840 (346)

A Comparison between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Congenital Factor VII Deficiency [PDF]

, 2015
In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 1/4g/kg, intravenously per week for 4 weeks, in a randomized fashion. The
Abolghasemi, H., Ahmadinejad, M., Baghaeipour, M.R., Dehdezi, B.K., Eshghi, P., Faranoush, M., Fayazfar, R., Heshmat, R., Hoorfar, H., Kamyar, K., Karimi, M., Khoeiny, B., Managhchi, M., Mehrvar, A., Mirbehbahani, N.B., Naderi, M., Toogeh, G.   +16 more
core  

Haemophilia care in Iraq; a multi-centre study

Journal of the Pakistan Medical Association
Objectives: To evaluate the level of care available to haemophilia patients. Method: The descriptive, retrospective analytical study was conducted from December 15, 2020, to March 1, 2021, after approval from the Mustansiriyah University, Baghdad ...
Nidal Karim Al Rahal, Meaad Kadhum Hassan, Obeida Amir Abid, Azeezah Mohammed Mohsin   +3 more
doaj   +1 more source

Web-based Application for the Population Pharmacokinetic Service (WAPPS)'s impact on dosage selection: a single paediatric centre experience

The Journal of Haemophilia Practice, 2021
Current treatment for severe haemophilia includes prophylactic factor replacement to prevent bleeding. Coagulation factor products have significant inter-patient variability in pharmacokinetic (PK) parameters.
Kwan Celia, Bhatt Mihir D., Strike Karen, Decker Kay, Matino Davide, Chan Anthony K.C.   +5 more
doaj   +1 more source

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors—A retrospective analysis

Haemophilia, 2018
Immune tolerance induction (ITI) is the gold standard for eradication of factor VIII inhibitors in severe haemophilia A; however, it usually requires treatment for extended periods with associated high burden on patients and healthcare resources.
M. Carcao, A. Shapiro, Janice M. Staber, Nina Hwang, C. Druzgal, Kenneth Lieuw, M. Belletrutti, Courtney D. Thornburg, Sanjay Ahuja, J. Morales-Arias, Jennifer A. Dumont, G. Miyasato, Elisa Tsao, N. Jain, S. Pipe   +14 more
semanticscholar   +1 more source

Quantifying Critical Quality Attributes of Protein Therapeutics by Sodium Dodecyl Sulfate–Capillary Gel Electrophoresis With Native Fluorescence Detection

ELECTROPHORESIS, EarlyView.
ABSTRACT In the biopharmaceutical industry, the sodium dodecyl sulfate–capillary gel electrophoresis (SDS–CGE) assay is often used to assess therapeutic critical quality attributes (CQAs). Traditional detection methods for SDS–CGE methods, such as ultraviolet (UV) absorbance and laser‐induced fluorescence (LIF), are widely used but come with ...
Zaifang Zhu
wiley   +1 more source

The relationship between target joints and direct resource use in severe haemophilia [PDF]

, 2018
Objectives Target joints are a common complication of severe haemophilia. While factor replacement therapy constitutes the majority of costs in haemophilia, the relationship between target joints and non drug-related direct costs (NDDCs) has not been ...
A Liras, A Srivastava, B Mihaylova, BA Konkle, C Knight, D Coughlan, FRMY Cassis, J Hanley, J O’Hara, JM Soucie, K Mulder, KA Johnson, M Bladen, M Iannone, MJ Manco-Johnson, PE Monahan, RLRL Bohn, S Donadel-Claeyssens, S Henrard, S Lobet, VE Price, VS Blanchette   +21 more
core   +1 more source

A creative approach to managing a case of haemophilia A with inhibitors in a low-resource country: case report

The Journal of Haemophilia Practice, 2023
The development of antibodies to therapeutic factor VIII, known as inhibitors, is a leading cause of morbidity and mortality in people with haemophilia. This is particularly challenging in areas where access to novel treatment options is limited.
Bhatia Simran, Archana M V, Bhat Vasudeva, Balthillya Ganesh M, Badagabettu Sulochana   +4 more
doaj   +1 more source

Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A

Haemophilia, 2017
Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half‐life (T1/2) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy.
Eric S. Mullins, O. Stasyshyn, M. Álvarez‐Román, D. Osman, R. Liesner, Werner Engl, Marlies Sharkhawy, B. Abbuehl   +7 more
semanticscholar   +1 more source

Exploring the Potential and Advancements of Circular RNA Therapeutics

Exploration, EarlyView.
Given the remarkable advantages in terms of stability, sustained expression profile, safety, wide range of druggable targets, scalable and cost‐effective manufacturing capabilities, circRNA is currently undergoing intensive investigation for various therapeutic applications such as vaccines, protein replacement, genetic disease treatment, gene therapy,
Lei Wang, Lianqing Wang, Chunbo Dong, Jialong Liu, Guoxin Cui, Shan Gao, Zhida Liu   +6 more
wiley   +1 more source

Clinical perspectives of emerging pathogens in bleeding disorders. [PDF]

, 2006
As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe ...
Bozzette, Samuel, Diamond, Michael, Koerper, Marion A, Kulkarni, Roshni, Ludlam, Christopher A, Powderly, William G, Ritchie, Bruce, Siegel, Jamie, Simmonds, Peter, Stanley, Samuel, Tapper, Michael L, von Depka, Mario   +11 more
core   +1 more source